Ardra .P.K*, Kavya Prathap, Sherin M Saji, Irene Thomas, Ansa Mathew
¹ Dr.Joseph marthoma institute of pharamaceutical science and research, India
*Corresponding Author: Dr.Joseph marthoma institute of pharamaceutical science and research, India Email: ardrapradeep1224@gmail.com.

Citation: LASMIDITAN: A NEW DRUG FOR ACUTE MIGRAINE: Sci J Phar and Pharmaceu Sci. 2025; 1(2): 001-006
Submitted: December 2024: Approved: January, 2025 Published: March, 2025

ABSTRACT: In related to the increased risk of cardio vascular (CV) diseases associated with migraine, there is a interest in the development of a new drug in the treatment of acute migraine which selectively act on non-vascular targets. Existing treatments are limited due to contra indications, or patient avoidance of side effects. This analysis show that 5-HT1F agonist have shown improved results in the treatment of migraine head ache. Also indicated the safety and efficacy of oral lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist in the migraine treatment. Research suggests that lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment in patient’s refractory to the acute migraine.

KEY WORDS: lasmiditan, 5HT-1F, migraine, headache, serotonin

https://doi.org/